Literature DB >> 25918154

Role of Apolipoprotein E in β-Amyloidogenesis: ISOFORM-SPECIFIC EFFECTS ON PROTOFIBRIL TO FIBRIL CONVERSION OF Aβ IN VITRO AND BRAIN Aβ DEPOSITION IN VIVO.

Yukiko Hori1, Tadafumi Hashimoto2, Hidetoshi Nomoto1, Bradley T Hyman3, Takeshi Iwatsubo4.   

Abstract

Human APOE ϵ4 allele is a strong genetic risk factor of Alzheimer disease. Neuropathological and genetic studies suggested that apolipoprotein E4 (apoE4) protein facilitates deposition of amyloid β peptide (Aβ) in the brain, although the mechanism whereby apoE4 increases amyloid aggregates remains elusive. Here we show that injection of Aβ protofibrils induced Aβ deposition in the brain of APP transgenic mice, suggesting that Aβ protofibrils acted as a seed for aggregation and deposition of Aβ in vivo. Injection of Aβ protofibrils together with apoE3 significantly attenuated Aβ deposition, whereas apoE4 did not have this effect. In vitro assays revealed that the conversion of Aβ protofibrils to fibrils progressed more slowly upon coincubation with apoE2 or apoE3 compared with that with apoE4. Aβ protofibrils complexed with apoE4 were less stable than those with apoE2 or apoE3. These data suggest that the suppression effect of apoE2 or apoE3 on the structural conversion of Aβ protofibrils to fibrils is stronger than those of apoE4, thereby impeding β-amyloid deposition.
© 2015 by The American Society for Biochemistry and Molecular Biology, Inc.

Entities:  

Keywords:  Alzheimer disease; amyloid; amyloid-β; apolipoprotein E; protein stability

Mesh:

Substances:

Year:  2015        PMID: 25918154      PMCID: PMC4463458          DOI: 10.1074/jbc.M114.622209

Source DB:  PubMed          Journal:  J Biol Chem        ISSN: 0021-9258            Impact factor:   5.157


  47 in total

1.  Amyloid beta-protein oligomerization: prenucleation interactions revealed by photo-induced cross-linking of unmodified proteins.

Authors:  G Bitan; A Lomakin; D B Teplow
Journal:  J Biol Chem       Date:  2001-07-05       Impact factor: 5.157

2.  The 'Arctic' APP mutation (E693G) causes Alzheimer's disease by enhanced Abeta protofibril formation.

Authors:  C Nilsberth; A Westlind-Danielsson; C B Eckman; M M Condron; K Axelman; C Forsell; C Stenh; J Luthman; D B Teplow; S G Younkin; J Näslund; L Lannfelt
Journal:  Nat Neurosci       Date:  2001-09       Impact factor: 24.884

Review 3.  Alzheimer's disease: genes, proteins, and therapy.

Authors:  D J Selkoe
Journal:  Physiol Rev       Date:  2001-04       Impact factor: 37.312

4.  Concentration-dependent inhibitory effects of apolipoprotein E on Alzheimer's beta-amyloid fibril formation in vitro.

Authors:  H Naiki; F Gejyo; K Nakakuki
Journal:  Biochemistry       Date:  1997-05-20       Impact factor: 3.162

5.  Diffusible, nonfibrillar ligands derived from Abeta1-42 are potent central nervous system neurotoxins.

Authors:  M P Lambert; A K Barlow; B A Chromy; C Edwards; R Freed; M Liosatos; T E Morgan; I Rozovsky; B Trommer; K L Viola; P Wals; C Zhang; C E Finch; G A Krafft; W L Klein
Journal:  Proc Natl Acad Sci U S A       Date:  1998-05-26       Impact factor: 11.205

6.  Evidence for seeding of beta -amyloid by intracerebral infusion of Alzheimer brain extracts in beta -amyloid precursor protein-transgenic mice.

Authors:  M D Kane; W J Lipinski; M J Callahan; F Bian; R A Durham; R D Schwarz; A E Roher; L C Walker
Journal:  J Neurosci       Date:  2000-05-15       Impact factor: 6.167

7.  Observation of metastable Abeta amyloid protofibrils by atomic force microscopy.

Authors:  J D Harper; S S Wong; C M Lieber; P T Lansbury
Journal:  Chem Biol       Date:  1997-02

8.  Characterization of the binding of amyloid-beta peptide to cell culture-derived native apolipoprotein E2, E3, and E4 isoforms and to isoforms from human plasma.

Authors:  D S Yang; J D Smith; Z Zhou; S E Gandy; R N Martins
Journal:  J Neurochem       Date:  1997-02       Impact factor: 5.372

9.  Apolipoprotein E isoform-dependent amyloid deposition and neuritic degeneration in a mouse model of Alzheimer's disease.

Authors:  D M Holtzman; K R Bales; T Tenkova; A M Fagan; M Parsadanian; L J Sartorius; B Mackey; J Olney; D McKeel; D Wozniak; S M Paul
Journal:  Proc Natl Acad Sci U S A       Date:  2000-03-14       Impact factor: 11.205

10.  Amyloid beta-protein fibrillogenesis. Detection of a protofibrillar intermediate.

Authors:  D M Walsh; A Lomakin; G B Benedek; M M Condron; D B Teplow
Journal:  J Biol Chem       Date:  1997-08-29       Impact factor: 5.157

View more
  17 in total

Review 1.  Study of Exosomes Shed New Light on Physiology of Amyloidogenesis.

Authors:  Guillaume van Niel
Journal:  Cell Mol Neurobiol       Date:  2016-03-17       Impact factor: 5.046

2.  Novel Sustainable-by-Design HDAC Inhibitors for the Treatment of Alzheimer's Disease.

Authors:  Luiz Antonio Soares Romeiro; Jéssica Larissa da Costa Nunes; Camila de Oliveira Miranda; Gabriella Simões Heyn Roth Cardoso; Andressa Souza de Oliveira; Annachiara Gandini; Tereza Kobrlova; Ondrej Soukup; Michele Rossi; Johanna Senger; Manfred Jung; Silvia Gervasoni; Giulio Vistoli; Sabrina Petralla; Francesca Massenzio; Barbara Monti; Maria Laura Bolognesi
Journal:  ACS Med Chem Lett       Date:  2019-03-29       Impact factor: 4.345

3.  Effect of APOE alleles on the glial transcriptome in normal aging and Alzheimer's disease.

Authors:  Alberto Serrano-Pozo; Zhaozhi Li; Ayush Noori; Huong N Nguyen; Aziz Mezlini; Liang Li; Eloise Hudry; Rosemary J Jackson; Bradley T Hyman; Sudeshna Das
Journal:  Nat Aging       Date:  2021-10-11

4.  Loss of kallikrein-related peptidase 7 exacerbates amyloid pathology in Alzheimer's disease model mice.

Authors:  Kiwami Kidana; Takuya Tatebe; Kaori Ito; Norikazu Hara; Akiyoshi Kakita; Takashi Saito; Sho Takatori; Yasuyoshi Ouchi; Takeshi Ikeuchi; Mitsuhiro Makino; Takaomi C Saido; Masahiro Akishita; Takeshi Iwatsubo; Yukiko Hori; Taisuke Tomita
Journal:  EMBO Mol Med       Date:  2018-03       Impact factor: 12.137

Review 5.  APOE-amyloid interaction: Therapeutic targets.

Authors:  Thomas Wisniewski; Eleanor Drummond
Journal:  Neurobiol Dis       Date:  2020-02-04       Impact factor: 5.996

6.  Apolipoprotein E and clusterin inhibit the early phase of amyloid-β aggregation in an in vitro model of cerebral amyloid angiopathy.

Authors:  Yoshinori Endo; Kazuhiro Hasegawa; Ryo Nomura; Hidetaka Arishima; Ken-Ichiro Kikuta; Taro Yamashita; Yasuteru Inoue; Mitsuharu Ueda; Yukio Ando; Mark R Wilson; Tadanori Hamano; Yasunari Nakamoto; Hironobu Naiki
Journal:  Acta Neuropathol Commun       Date:  2019-01-28       Impact factor: 7.801

7.  The effects of aerobic training before and after the induction of Alzheimer's disease on ABCA1 and APOE mRNA expression and the level of soluble Aβ1-42 in the hippocampus of male Wistar rats.

Authors:  Zahra Sarlak; Mahtab Moazzami; Moazzami Attarzadeh Hosseini; Reza Gharakhanlou
Journal:  Iran J Basic Med Sci       Date:  2019-04       Impact factor: 2.699

Review 8.  Some Candidate Drugs for Pharmacotherapy of Alzheimer's Disease.

Authors:  Barbara Miziak; Barbara Błaszczyk; Stanisław J Czuczwar
Journal:  Pharmaceuticals (Basel)       Date:  2021-05-13

9.  GPR120 signaling controls amyloid-β degrading activity of matrix metalloproteinases.

Authors:  Kazunori Kikuchi; Takuya Tatebe; Yuki Sudo; Miyabishara Yokoyama; Kiwami Kidana; Yung Wen Chiu; Sho Takatori; Makoto Arita; Yukiko Hori; Taisuke Tomita
Journal:  J Neurosci       Date:  2021-06-04       Impact factor: 6.167

Review 10.  Passive immunotherapies targeting Aβ and tau in Alzheimer's disease.

Authors:  Steven S Plotkin; Neil R Cashman
Journal:  Neurobiol Dis       Date:  2020-07-16       Impact factor: 7.046

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.